Perinatal Outcomes in Patients With Elevated sFlt-1/PlGF Ratio
NCT ID: NCT06403722
Last Updated: 2024-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
190 participants
OBSERVATIONAL
2023-11-15
2024-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of the sFlt-1/PlGF Ratio on Medical Decision-making and on Maternal and Neonatal Outcomes in Women Suspected of Preeclampsia
NCT06314555
sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia
NCT05228002
Angiogenic Factors in the Conservative Management of Gestational Hypertension
NCT06123377
Preeclampsia Ratio (sFlt-1/PlGF)
NCT03289611
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
NCT04766866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sFlt-1/PlGF: 110-205
Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 110-205.
Standard of care
No intervention. Clinical evolution was recorded, looking for perinatal complications.
sFlt-1/PlGF: 206-654
Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 206-654.
Standard of care
No intervention. Clinical evolution was recorded, looking for perinatal complications.
sFlt-1/PlGF: 655-999
Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF between 655-999.
Standard of care
No intervention. Clinical evolution was recorded, looking for perinatal complications.
sFlt-1/PlGF > 1000
Subjects with suspicion of preeclampsia, with gestational age between 24 - 36 6/7 weeks and sFlt-1/PlGF above 1000.
Standard of care
No intervention. Clinical evolution was recorded, looking for perinatal complications.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard of care
No intervention. Clinical evolution was recorded, looking for perinatal complications.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age between 24 - 36 6/7
* sFlt-1/PlGF \> 110
Exclusion Criteria
* Absence of sFLt-1/PlGF ratio result.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saint Thomas Hospital, Panama
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Osvaldo A. Reyes T.
Head of the research deparment
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint Thomas H
Panama City, , Panama
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-631
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.